Trial Outcomes & Findings for Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma (NCT NCT02073097)
NCT ID: NCT02073097
Last Updated: 2024-05-29
Results Overview
Highest dose administered when no more than 1 out of 6 patients experience lose limiting toxicity below the maximally administered dose.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
48 participants
Primary outcome timeframe
Through cycle 6 (each cycle is 21 days)
Results posted on
2024-05-29
Participant Flow
Participant milestones
| Measure |
Phase I CR-CHOP Level -2
Dose level -2:
Carfilzomib: 11 mg/m\^2 on day 1 and 2 every 21 days, cycles 1-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Level -1
Dose Level -1:
Carfilzomib: 15 mg/m\^2 on days 1 and 2 every 21 days, cycles 1-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 1
Dose Level 1:
Carfilzomib: 20 mg/m\^2 days 1,2 every 21 days, cycles 1-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 2
Dose Level 2:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 27 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 3
Dose Level 3:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 36 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 4
Dose Level 4:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 45 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 5
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase II CR-CHOP Dose Level 5
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
9
|
3
|
3
|
3
|
6
|
24
|
|
Overall Study
COMPLETED
|
0
|
0
|
9
|
3
|
3
|
3
|
6
|
18
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
Reasons for withdrawal
| Measure |
Phase I CR-CHOP Level -2
Dose level -2:
Carfilzomib: 11 mg/m\^2 on day 1 and 2 every 21 days, cycles 1-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Level -1
Dose Level -1:
Carfilzomib: 15 mg/m\^2 on days 1 and 2 every 21 days, cycles 1-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 1
Dose Level 1:
Carfilzomib: 20 mg/m\^2 days 1,2 every 21 days, cycles 1-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 2
Dose Level 2:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 27 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 3
Dose Level 3:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 36 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 4
Dose Level 4:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 45 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 5
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase II CR-CHOP Dose Level 5
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6 CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
Overall Study
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
Overall Study
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Baseline characteristics by cohort
| Measure |
Phase I CR-CHOP Level -2
Dose level -2:
Carfilzomib: 11 mg/m\^2 on day 1 and 2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Level -1
Dose Level -1:
Carfilzomib: 15 mg/m\^2 on days 1 and 2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 1
n=9 Participants
Dose Level 1:
Carfilzomib: 20 mg/m\^2 days 1,2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 2
n=3 Participants
Dose Level 2:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 27 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 3
n=3 Participants
Dose Level 3:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 36 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 4
n=3 Participants
Dose Level 4:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 45 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 5
n=6 Participants
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase II CR-CHOP Dose Level 5
n=24 Participants
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Total
n=48 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
20-29 years old
|
—
|
—
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
|
Age, Customized
30-39 years old
|
—
|
—
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
|
Age, Customized
40-49 years old
|
—
|
—
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
|
Age, Customized
50-59 years old
|
—
|
—
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
12 Participants
n=42 Participants
|
|
Age, Customized
60-69 years old
|
—
|
—
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
10 Participants
n=42 Participants
|
|
Age, Customized
70-79 years old
|
—
|
—
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
10 Participants
n=24 Participants
|
15 Participants
n=42 Participants
|
|
Sex: Female, Male
Female
|
—
|
—
|
7 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
8 Participants
n=24 Participants
|
23 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
—
|
—
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
16 Participants
n=24 Participants
|
25 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
—
|
—
|
9 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
23 Participants
n=24 Participants
|
47 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Asian
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Black or African American
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
White
|
—
|
—
|
9 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
24 Participants
n=24 Participants
|
48 Participants
n=42 Participants
|
|
Race (NIH/OMB)
More than one race
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
—
|
—
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Region of Enrollment
United States
|
—
|
—
|
9 participants
n=5 Participants
|
3 participants
n=4 Participants
|
3 participants
n=21 Participants
|
3 participants
n=8 Participants
|
6 participants
n=8 Participants
|
24 participants
n=24 Participants
|
48 participants
n=42 Participants
|
PRIMARY outcome
Timeframe: Through cycle 6 (each cycle is 21 days)Population: The number of subjects that were on the phase I cohort.
Highest dose administered when no more than 1 out of 6 patients experience lose limiting toxicity below the maximally administered dose.
Outcome measures
| Measure |
Rituximab, Combination Chemotherapy, Carfilzomib
n=24 Participants
Participants receive (every 21 day cycle):
* Rituximab IV over at least 90 minutes on day 2
* Carfilzomib IV over 30 minutes on days 1, and 2
* Cyclophosphamide IV over 30-60 minutes on day 3
* Doxorubicin hydrochloride IV over 3-5 minutes on day 3
* Vincristine sulfate IV over 1 minute on day 3
* Prednisone PO on days 3-7 any time
* Pegfilgrastim day 4
* Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6
Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Recommended Phase II Dose (Phase I)
Days 1, 2 of cycle 1
|
20 mg/m^2
|
|
Recommended Phase II Dose (Phase I)
Days 1, 2 every 21 days for cycles 2-6
|
56 mg/m^2
|
SECONDARY outcome
Timeframe: 31 months after treatmentPopulation: 24 participants were enrolled in Phase II.
PFS will be estimated using a Kaplan-Meier curve. Progression-free Survival (PFS) is defined as the time from entry onto study until lymphoma progression or death from any cause. Participants was evaluated utilizing RECIST v1.0 criteria at baseline, 3 months after beginning treatment, end of treatment (6 cycles of therapy), and at 6 month, 12 month, and 24 month follow up visit. RECIST v1.0 criteria for Malignant Lymphoma use the following categories of response: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Relapse and Progression (PD).
Outcome measures
| Measure |
Rituximab, Combination Chemotherapy, Carfilzomib
n=24 Participants
Participants receive (every 21 day cycle):
* Rituximab IV over at least 90 minutes on day 2
* Carfilzomib IV over 30 minutes on days 1, and 2
* Cyclophosphamide IV over 30-60 minutes on day 3
* Doxorubicin hydrochloride IV over 3-5 minutes on day 3
* Vincristine sulfate IV over 1 minute on day 3
* Prednisone PO on days 3-7 any time
* Pegfilgrastim day 4
* Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6
Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Progression Free Survival (Phase II)
|
79 percentage of participants
|
SECONDARY outcome
Timeframe: 31 months after treatmentPopulation: 24 participants were enrolled to Phase II.
Overall survival will be estimated with a Kaplan-Meier curve. Overall survival is defined as the time from entry onto study until lymphoma progression or death from any cause.
Outcome measures
| Measure |
Rituximab, Combination Chemotherapy, Carfilzomib
n=24 Participants
Participants receive (every 21 day cycle):
* Rituximab IV over at least 90 minutes on day 2
* Carfilzomib IV over 30 minutes on days 1, and 2
* Cyclophosphamide IV over 30-60 minutes on day 3
* Doxorubicin hydrochloride IV over 3-5 minutes on day 3
* Vincristine sulfate IV over 1 minute on day 3
* Prednisone PO on days 3-7 any time
* Pegfilgrastim day 4
* Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6
Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Overall Survival (Phase II)
|
87 % of participants analyzed
|
SECONDARY outcome
Timeframe: 31 months after treatmentPopulation: 24 participants were enrolled to Phase II.
The percentage of patients with a complete response as defined by a complete disappearance of all detectable clinical evidence of disease, and disease-related symptoms if present prior to therapy
Outcome measures
| Measure |
Rituximab, Combination Chemotherapy, Carfilzomib
n=24 Participants
Participants receive (every 21 day cycle):
* Rituximab IV over at least 90 minutes on day 2
* Carfilzomib IV over 30 minutes on days 1, and 2
* Cyclophosphamide IV over 30-60 minutes on day 3
* Doxorubicin hydrochloride IV over 3-5 minutes on day 3
* Vincristine sulfate IV over 1 minute on day 3
* Prednisone PO on days 3-7 any time
* Pegfilgrastim day 4
* Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6
Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Complete Response Rate (Phase II)
|
70 percentage of participants
|
SECONDARY outcome
Timeframe: 31 months after treatmentPopulation: 24 participants were enrolled in Phase II.
The percentage of patients with a partial response as defined a \>50% decrease in the sum of the product of the diameter of up to six of the largest nodes; no increase in the any node, liver, or spleen; no new sites of disease.
Outcome measures
| Measure |
Rituximab, Combination Chemotherapy, Carfilzomib
n=24 Participants
Participants receive (every 21 day cycle):
* Rituximab IV over at least 90 minutes on day 2
* Carfilzomib IV over 30 minutes on days 1, and 2
* Cyclophosphamide IV over 30-60 minutes on day 3
* Doxorubicin hydrochloride IV over 3-5 minutes on day 3
* Vincristine sulfate IV over 1 minute on day 3
* Prednisone PO on days 3-7 any time
* Pegfilgrastim day 4
* Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6
Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Partial Response Rate (Phase II)
|
19 percentage of participants
|
Adverse Events
Phase I CR-CHOP Level -2
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Phase I CR-CHOP Level -1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Phase I CR-CHOP Dose Level 1
Serious events: 2 serious events
Other events: 8 other events
Deaths: 1 deaths
Phase I CR-CHOP Dose Level 2
Serious events: 2 serious events
Other events: 3 other events
Deaths: 1 deaths
Phase I CR-CHOP Dose Level 3
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
Phase I CR-CHOP Dose Level 4
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Phase I CR-CHOP Dose Level 5
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
Phase II CR-CHOP Dose Level 5
Serious events: 8 serious events
Other events: 22 other events
Deaths: 2 deaths
Serious adverse events
| Measure |
Phase I CR-CHOP Level -2
Dose level -2:
Carfilzomib: 11 mg/m\^2 on day 1 and 2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Level -1
Dose Level -1:
Carfilzomib: 15 mg/m\^2 on days 1 and 2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 1
n=9 participants at risk
Dose Level 1:
Carfilzomib: 20 mg/m\^2 days 1,2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 2
n=3 participants at risk
Dose Level 2:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 27 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 3
n=3 participants at risk
Dose Level 3:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 36 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 4
n=3 participants at risk
Dose Level 4:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 45 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 5
n=6 participants at risk
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase II CR-CHOP Dose Level 5
n=24 participants at risk
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Atrioventricular block complete
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Supraventricular tachycardia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Blood and lymphatic system disorders
Anemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Heart Failure
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Diarrhea
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Enterocolitis infectious
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Fever
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Gastric hemorrhage
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Hypotension
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Nausea
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Sinus tachycardia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Influenza
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Vomiting
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Platelet count decreased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Infusion related reaction
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Lung Infection
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Upper respiratory infection
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Treatment related secondary malignancy
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Thromboembolic event
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Atrial fibrillation
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Infusion site extravasation
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Port containment
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Syncope
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Hematoma
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Abdominal pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Neutrophil count decreased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Hypercalcemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Chills
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
Other adverse events
| Measure |
Phase I CR-CHOP Level -2
Dose level -2:
Carfilzomib: 11 mg/m\^2 on day 1 and 2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Level -1
Dose Level -1:
Carfilzomib: 15 mg/m\^2 on days 1 and 2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 1
n=9 participants at risk
Dose Level 1:
Carfilzomib: 20 mg/m\^2 days 1,2 every 21 days, cycles 1-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 2
n=3 participants at risk
Dose Level 2:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 27 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 3
n=3 participants at risk
Dose Level 3:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 36 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 4
n=3 participants at risk
Dose Level 4:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 45 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase I CR-CHOP Dose Level 5
n=6 participants at risk
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
Phase II CR-CHOP Dose Level 5
n=24 participants at risk
Dose Level 5:
Carfilzomib: 20 mg/m\^2 days 1,2 of cycle 1 followed by 56 mg/m\^2 days 1,2 every 21 days for cycles 2-6
CHOP: Standard dose on day 3 every 21 days Rituximab standard dose on Day 2
|
|---|---|---|---|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
4/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Abdominal pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Renal and urinary disorders
Acute kidney injury
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Alanine aminotransferase increased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
22.2%
2/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Alkaline phosphatase increased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
44.4%
4/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
4/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Blood and lymphatic system disorders
Anemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
3/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
29.2%
7/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Anorexia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Aspartate aminotransferase increased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
3/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Atrial fibrillation
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Atrioventricular block complete
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Bloating
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Eye disorders
Blurred vision
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Reproductive system and breast disorders
Breast pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Injury, poisoning and procedural complications
Bruising
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Syncopal episode
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Cerebrospinal fluid leakage
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Chest wall pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Chills
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Colitis
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Constipation
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
44.4%
4/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
25.0%
6/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
4/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Diarrhea
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
22.2%
2/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
8/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Dizziness
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
4/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Eye disorders
Dry eye
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Dry mouth
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Dysgeusia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
4/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Dyspepsia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Dysphagia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Hemorrhoids
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
22.2%
2/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
50.0%
3/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
25.0%
6/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Ear and labyrinth disorders
Impaired Balance
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Edema face
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Edema limbs
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
4/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Ejection fraction decreased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Eye disorders
Eye Spasms
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Injury, poisoning and procedural complications
Fall
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Fatigue
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
44.4%
4/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
50.0%
3/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
29.2%
7/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Fever
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Flu like symptoms
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Night Sweats
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Cold Sensitivity in Mouth
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Mental Fog
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Headache
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
22.2%
2/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Heart failure
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Hematoma
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Renal and urinary disorders
Hematuria
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Hemoglobin increased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Hypertension
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Endocrine disorders
Hyperthyroidism
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
25.0%
6/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Hypotension
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Yeast Infection
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Infusion related reaction
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Injection site reaction
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
INR increased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Psychiatric disorders
Insomnia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
22.2%
2/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
20.8%
5/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Elevated serum chloride
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Decreased Uric Acid
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Irritability
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Lymphocyte count decreased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
20.8%
5/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Metabolism and nutrition disorders
Elevated Glucose
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Ear and labyrinth disorders
Middle ear inflammation
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Mitral valve disease
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Mucosal infection
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Mucositis oral
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Nail ridging
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
22.2%
2/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Nausea
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
54.2%
13/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Neck edema
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Neutrophil count decreased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
55.6%
5/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Non-cardiac chest pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Oral pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Pain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
3/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
20.8%
5/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Palpitations
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Paresthesia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
3/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Peripheral motor neuropathy
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
55.6%
5/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
50.0%
3/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
37.5%
9/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Platelet count decreased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
3/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
2/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
20.8%
5/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Postnasal drip
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Presyncope
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Renal and urinary disorders
Urinary Hesitancy
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Chest congestion
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal Drainage
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus drainage
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Intermittent Shortness of Breath
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Irritated Throat
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Eye disorders
Scleral disorder
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Cardiac disorders
Sinus tachycardia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Sinusitis
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Skin Discoloration - RIght Leg
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Petechia - Abdomen from Lovenox
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Skin - Other - Peeling of skin of fingers
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Skin infection
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Social circumstances
Insomnia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
16.7%
1/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Nervous system disorders
Syncope
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Thromboembolic event
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
22.2%
2/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Ear and labyrinth disorders
Tinnitus
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Upper gastrointestinal hemorrhage
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Upper respiratory infection
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
11.1%
1/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Renal and urinary disorders
Urinary frequency
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
12.5%
3/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Urinary tract infection
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Voice alteration
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Gastrointestinal disorders
Vomiting
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
3/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
29.2%
7/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Weight gain
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Weight loss
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
White blood cell decreased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
3/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
66.7%
2/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Ear and labyrinth disorders
Hearing Impariment
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
33.3%
1/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
General disorders
Malaise
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Vascular disorders
Flushing
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Investigations
Creatinine increased
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
8.3%
2/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Renal and urinary disorders
Renal and urinary disorders - Other
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Respiratory, thoracic and mediastinal disorders
Influenza
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Eye disorders
Conjunctivitis
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Psychiatric disorders
Confusion
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
|
Infections and infestations
Infections and infestations - Other
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
—
0/0 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/9 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/3 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
0.00%
0/6 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
4.2%
1/24 • Adverse events were collected from time of participants on-study through follow-up (up to 31 months following treatment)
All-cause mortality is zero for Phase I CR-CHOP Level -2 and Phase I CR-CHOP Level -1 because no participants were enrolled to these arms.
|
Additional Information
Dr. Brian T. Hill
Cleveland Clinic Foundation, Case Comprehensive Cancer Center
Phone: 1-866-223 8100
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place